Major players in the research antibodies and reagents market are Becton Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., F. Hoffmann La-Roche Ltd, Merck KGaA, PerkinElmer Inc., Lonza Group AG, Abcam plc, GenScript Biotech Corporation, and Bio-Techne Corporation.
The global research antibodies and reagents market is expected to grow from $10.35 billion in 2019 to $12.64 billion in 2020 at a compound annual growth rate (CAGR) of 22.08%. The growth is mainly due to the COVID-19 outbreak that has led to an increase in demand for antibodies to treat affected patients. The market is then expected to stabilize and reach $13.19 billion in 2023 at a CAGR of 1.43%.
The research antibodies and reagents market consists of sales of research antibodies, reagents and related services by entities (organizations, sole traders and partnerships) that produce research antibodies and reagents to diagnose and treat different diseases. The revenue generated by the market includes the sales of research antibodies in the form of primary and secondary antibodies extracted from sources such as mouse, rabbit and others, and reagents like stains & dyes, media & serum, fixatives, buffers, probe, solvents, enzymes and others. The companies involved in the research antibodies and reagents market are primarily engaged in developing antibodies and reagents for the application of proteomics, genomics, drug discovery and development by the pharmaceutical & biotechnology industries, academic & research institutes and contract research organizations.
The research antibodies and reagents market covered in this market is segmented by technology into western blot; immunofluorescence; immunohistochemistry; flow cytometry; enzyme-linked immunosorbent assay (ELISA); multiplex immunosorbent assay; immunoprecipitation; others, by application into proteomics; drug discovery & development; genomics, and by end-user into pharmaceutical & biotechnology industry; academic & research institutes; contract research organizations (CROS).
In 2019, LifeSpan BioSciences Inc, a US-based global molecular pathology company, acquired Everest Biotech Ltd for an undisclosed amount. The acquisition is expected to strengthen LifeSpan Biosciences’ position in the research reagent market and will broaden the product portfolio over 500,000 monoclonal and polyclonal primary antibodies to include virtually every protein in the proteome. Everest Biotech is a UK-based anti-peptide and antigen affinity purified goat polyclonal antibodies manufacturer, which was established in 2000.
Reproducibility issues of antibodies and reagents is expected to hamper the growth of the research antibodies and reagents market. Reproducibility is the ability of an experiment or calculation to be duplicated by other researchers working independently. In 2015, the prevalence of irreproducible preclinical research exceeded 50%, resulting in approximately $28 billion spent on preclinical research every year. Among the irreproducible research, the largest fraction of about 36% is assigned to biological reagents, which amounts to $10 billion annually. This huge research wastage expenses are due to insufficiently validated antibodies and irreproducible reagents that are not appropriate for the target proteins. Thus, reproducibility issues of antibodies and reagents are expected to restrain the market growth.
Technological advancements in the area of purification of antibodies and reagents show opportunities for the growth of the research antibodies and reagents market during the forecast period. Irreproducible antibodies and reagents are a major challenge for the industry as this will affect the outcome of the research. In 2019, Genscript announced the launch of an AmMag technology, which is a semi-automatic purification instrument, that accelerates the purification process from days to hours. The AmMag SA was developed under the license agreement with Amgen.
Increasing investment in medical and health research and development (R&D) is predicted to contribute to the growth of the research antibodies and reagents market. In the field of life science research, antibodies and reagents are essential components for the investigation of biological processes or causes of diseases through careful experimentation, observation, laboratory work, analysis, and testing. According to the American Association for the Advancement of Science’s (AAAS) statistics published in December 2019, the total investment in medical and health research in the US grew by 6.4% from 2017 to 2018 to reach $194.2 billion. The health industry invested $129.5 billion (66.7%), followed by federal agencies investments of $43 billion (22.2%), and $21.7 billion (11.2%) invested by foundations, state & local governments, academic research institutions, and voluntary health associations. Thus, increasing investment in healthcare research and development will increase the utilization of research antibodies and reagents.
Our reports have been used by over 10K customers, including:
Arteriosclerosis (Cardiovascular) - Drugs in Development, 2021 Summary Arteriosclerosis (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Arteriosclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arteriosclerosis,...
Muscle Atrophy (Musculoskeletal) - Drugs in Development, 2021 Summary Muscle Atrophy (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Muscle Atrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscle...
Neuroendocrine Cancer (Oncology) - Drugs in Development, 2021 Summary Neuroendocrine Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Neuroendocrine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for...
Opioid Induced Side Effects (Oncology) - Drugs in Development, 2021 Summary Opioid Induced Side Effects (Oncology) - Drugs in Development, 2021 provides an overview of the Opioid Induced Side Effects pipeline landscape. The report provides comprehensive information on the therapeutics under...
Proctitis (Gastrointestinal) - Drugs in Development, 2021 Summary Proctitis (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Proctitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Proctitis, complete...
Ulcers (Gastrointestinal) - Drugs in Development, 2021 Summary Ulcers (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Ulcers pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ulcers, complete with analysis...
Bronchiolitis Obliterans (Respiratory) - Drugs in Development, 2021 Summary Bronchiolitis Obliterans (Respiratory) - Drugs in Development, 2021 provides an overview of the Bronchiolitis Obliterans pipeline landscape. The report provides comprehensive information on the therapeutics under development...
Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 Summary Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Acute Liver Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development...
Genito Urinary System And Sex Hormones (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021 Summary Genito Urinary System And Sex Hormones (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021 provides an overview of the Genito Urinary System And Sex Hormones pipeline...
Therapy
Research And Development
Drug Development
World
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.